» Articles » PMID: 37924460

Excess Pancreatic Cancer Risk Due to Smoking and Modifying Effect of Quitting Smoking: The Multiethnic Cohort Study

Overview
Specialties Oncology
Public Health
Date 2023 Nov 4
PMID 37924460
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Risk factors for pancreatic cancer include racial/ethnic disparities and smoking. However, risk trajectories by smoking history and race/ethnicity are unknown. We examined the association of smoking with pancreatic cancer by race/ethnicity to generate age-specific incidence estimates by smoking history.

Methods: We modeled pancreatic cancer incidence by race/ethnicity, age, pack-years, and years-quit using an excess relative risk model for 182,011 Multiethnic Cohort participants. We tested heterogeneity of smoking variables and pancreatic cancer by race/ethnicity and predicted incidence by smoking history.

Results: We identified 1,831 incident pancreatic cancer cases over an average 19.3 years of follow-up. Associations of pack-years (p interaction by race/ethnicity = 0.41) and years-quit (p interaction = 0.83) with pancreatic cancer did not differ by race/ethnicity. Fifty pack-years smoked was associated with 91% increased risk (95% CI 54%, 127%) relative to never smokers in the combined sample. Every year quit corresponded to 9% decreased excess risk (95% CI 2%, 15%) from pack-years smoked. Differences in baseline pancreatic cancer risk across racial/ethnic groups (p < 0.001) translated to large differences in risk for smokers at older ages across racial/ethnic groups (65-122 cases per 100,000 at age 70).

Conclusion: Smoking pack-years were positively associated with elevated pancreatic cancer risk. Predicted risk trajectories showed a high impact of smoking cessation at < 65 years. Although we did not identify significant heterogeneity in the association of pack-years or years quit with pancreatic cancer risk, current smoker risk varied greatly by race/ethnicity in later life due to large differences in baseline risk.

Citing Articles

Immunohistochemical Evaluation of the Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma.

Breaza G, Closca R, Cindrea A, Hut F, Cretu O, Sima L Diagnostics (Basel). 2025; 15(5).

PMID: 40075893 PMC: 11899021. DOI: 10.3390/diagnostics15050646.


Pancreatic Ductal Adenocarcinoma (PDAC): A Review of Recent Advancements Enabled by Artificial Intelligence.

Mukund A, Afridi M, Karolak A, Park M, Permuth J, Rasool G Cancers (Basel). 2024; 16(12).

PMID: 38927945 PMC: 11201559. DOI: 10.3390/cancers16122240.

References
1.
Kalser M, Barkin J, MacIntyre J . Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer. 1985; 56(2):397-402. DOI: 10.1002/1097-0142(19850715)56:2<397::aid-cncr2820560232>3.0.co;2-i. View

2.
Gram I, Park S, Maskarinec G, Wilkens L, Haiman C, Le Marchand L . Smoking and breast cancer risk by race/ethnicity and oestrogen and progesterone receptor status: the Multiethnic Cohort (MEC) study. Int J Epidemiol. 2019; 48(2):501-511. PMC: 6469313. DOI: 10.1093/ije/dyy290. View

3.
Schulte A, Pandeya N, Tran B, Fawcett J, Fritschi L, Risch H . Cigarette smoking and pancreatic cancer risk: more to the story than just pack-years. Eur J Cancer. 2014; 50(5):997-1003. DOI: 10.1016/j.ejca.2013.12.014. View

4.
Arslan A, Helzlsouer K, Kooperberg C, Shu X, Steplowski E, Bueno-de-Mesquita H . Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med. 2010; 170(9):791-802. PMC: 2920035. DOI: 10.1001/archinternmed.2010.63. View

5.
Lugo A, Peveri G, Bosetti C, Bagnardi V, Crippa A, Orsini N . Strong excess risk of pancreatic cancer for low frequency and duration of cigarette smoking: A comprehensive review and meta-analysis. Eur J Cancer. 2018; 104:117-126. DOI: 10.1016/j.ejca.2018.09.007. View